MXPA02002546A - Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina. - Google Patents

Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina.

Info

Publication number
MXPA02002546A
MXPA02002546A MXPA02002546A MXPA02002546A MXPA02002546A MX PA02002546 A MXPA02002546 A MX PA02002546A MX PA02002546 A MXPA02002546 A MX PA02002546A MX PA02002546 A MXPA02002546 A MX PA02002546A MX PA02002546 A MXPA02002546 A MX PA02002546A
Authority
MX
Mexico
Prior art keywords
antagonist
pharmaceutical compositions
receptor agonist
adenosine receptor
adenosine
Prior art date
Application number
MXPA02002546A
Other languages
English (en)
Spanish (es)
Inventor
Pnina Fishman
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13186499A external-priority patent/IL131864A0/xx
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of MXPA02002546A publication Critical patent/MXPA02002546A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MXPA02002546A 1999-09-10 2000-09-08 Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina. MXPA02002546A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13186499A IL131864A0 (en) 1999-09-10 1999-09-10 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
IL13368099A IL133680A0 (en) 1999-09-10 1999-12-23 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
PCT/IL2000/000550 WO2001019360A2 (en) 1999-09-10 2000-09-08 Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist

Publications (1)

Publication Number Publication Date
MXPA02002546A true MXPA02002546A (es) 2003-07-21

Family

ID=26323880

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02002546A MXPA02002546A (es) 1999-09-10 2000-09-08 Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina.

Country Status (19)

Country Link
US (2) US7064112B1 (https=)
EP (1) EP1261322B1 (https=)
JP (2) JP4980530B2 (https=)
KR (2) KR100584797B1 (https=)
CN (1) CN100358512C (https=)
AU (1) AU782826B2 (https=)
BR (1) BR0013905A (https=)
CA (1) CA2384111C (https=)
DE (1) DE60037277T2 (https=)
DK (1) DK1261322T3 (https=)
ES (1) ES2296637T3 (https=)
HK (1) HK1052653B (https=)
HU (1) HU226913B1 (https=)
IL (1) IL133680A0 (https=)
MX (1) MXPA02002546A (https=)
PL (1) PL199852B1 (https=)
PT (1) PT1261322E (https=)
RU (1) RU2239455C2 (https=)
WO (1) WO2001019360A2 (https=)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121272A (en) * 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
AU8181701A (en) 2000-06-21 2002-01-02 Hoffmann La Roche Benzothiazole derivatives
JP4012070B2 (ja) * 2001-01-16 2007-11-21 カン−フィテ・バイオファーマ・リミテッド ウイルスの複製を阻害するためのアデノシンａ３受容体アゴニストの使用
US20020115635A1 (en) * 2001-02-21 2002-08-22 Pnina Fishman Modulation of GSK-3beta activity and its different uses
US20040204481A1 (en) * 2001-04-12 2004-10-14 Pnina Fishman Activation of natural killer cells by adenosine A3 receptor agonists
US7049303B2 (en) 2001-11-07 2006-05-23 Medical Research Council Inhibition of viruses
US7414036B2 (en) 2002-01-25 2008-08-19 Muscagen Limited Compounds useful as A3 adenosine receptor agonists
EP1554583B1 (en) * 2002-10-22 2007-08-22 Can-Fite Biopharma Ltd. The use of the a3 adenosine receptor as a marker for a disease state
US7087761B2 (en) 2003-01-07 2006-08-08 Hoffmann-La Roche Inc. Cyclization process for substituted benzothiazole derivatives
CN1956983B (zh) 2004-05-24 2010-05-26 弗·哈夫曼-拉罗切有限公司 4-羟基-4-甲基-哌啶-1-甲酸(4-甲氧基-7-吗啉-4-基-苯并噻唑-2-基)-酰胺
CN103087133B (zh) 2004-05-26 2016-09-14 伊诺泰克制药公司 嘌呤衍生物作为腺苷a1受体激动剂及其用法
US7825102B2 (en) 2004-07-28 2010-11-02 Can-Fite Biopharma Ltd. Treatment of dry eye conditions
CN101437526A (zh) 2004-09-20 2009-05-20 伊诺泰克制药公司 嘌呤衍生物及其用法
EP1799221A1 (en) * 2004-10-15 2007-06-27 Cv Therapeutics, Inc. Method of preventing and treating airway remodeling and pulmonary inflammation using a2b adenosine receptor antagonists
JP4633123B2 (ja) 2004-11-05 2011-02-16 エフ．ホフマン−ラ ロシュ アーゲー イソニコチン酸誘導体の製造方法
JP2008519029A (ja) * 2004-11-08 2008-06-05 キャン−ファイト・バイオファーマ・リミテッド 加速骨吸収の治療的処置
WO2007040565A2 (en) * 2004-11-22 2007-04-12 King Pharmaceuticals Research & Development, Inc. Enhancing treatment of cancer and hif-1 mediated disoders with adenosine a3 receptor antagonists
DE602006012815D1 (de) 2005-03-23 2010-04-22 Hoffmann La Roche Acetylenylpyrazolopyrimidinderivate als mglur2-antagonsten
AU2006298829B2 (en) 2005-09-27 2011-03-03 F. Hoffmann-La Roche Ag Oxadiazolyl pyrazolo-pyrimidines as mGluR2 antagonists
EA015683B1 (ru) 2005-11-30 2011-10-31 Инотек Фармасьютикалз Корпорейшн Производные пурина и способы их применения
BRPI0621052A2 (pt) * 2006-01-27 2012-07-17 Can Fite Biopharma Ltd uso de um agonista de receptor de adenosina a3 (a3ar)
WO2008023362A2 (en) * 2006-08-21 2008-02-28 Can-Fite Biopharma Ltd. Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
MX2009003750A (es) * 2006-10-06 2009-06-18 Univ Pennsylvania Suministro eficiente de antagonistas del receptor de adenosina a3 de especies cruzadas, para reducir la presion intraocular.
GB0625100D0 (en) * 2006-12-15 2007-01-24 Univ Murcia Epigallocatechin-3-gallate compositions for cancer therapy and chemoprotection
US20090088403A1 (en) * 2007-05-07 2009-04-02 Randy Blakely A3 adenosine receptors as targets for the modulation of central serotonergic signaling
CA2694983A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Treatments of b-cell proliferative disorders
US20090047243A1 (en) * 2007-07-17 2009-02-19 Richard Rickles Combinations for the treatment of b-cell proliferative disorders
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
WO2010027935A1 (en) * 2008-09-08 2010-03-11 Merck Sharp & Dohme Corp. Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
JP5849044B2 (ja) 2009-05-17 2016-01-27 キャン−ファイト バイオファーマ リミテッド 眼圧低下のためのａ３アデノシン受容体作動薬
WO2011010306A1 (en) 2009-07-21 2011-01-27 Ramot At Tel-Aviv University Ltd. A3 adenosine receptor ligands for modulation of pigmentation
WO2011074903A2 (ko) * 2009-12-17 2011-06-23 이화여자대학교 산학협력단 Ａ3 아데노신 수용체 효능제를 포함하는 약제학적 조성물
LT2523669T (lt) 2010-01-11 2017-04-25 Inotek Pharmaceuticals Corporation Akispūdžio mažinimo būdas, derinys ir rinkinys
MX2012010006A (es) 2010-03-03 2013-01-17 Us Gov Health & Human Serv Agonistas de a3ar para el tratamiento de uveitis.
PH12012501906A1 (en) 2010-03-26 2013-01-14 Inotek Pharmaceuticals Corp Method of reducing intraocular pressure in humans using n6 -cyclopentyladenosine (cpa), cpa derivatives or prodrugs thereof
WO2011123518A1 (en) 2010-03-31 2011-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adenosine receptor agonists for the treatment and prevention of vascular or joint capsule calcification disorders
UA117095C2 (uk) 2011-12-22 2018-06-25 Аліос Біофарма, Інк. Нуклеозидна сполука або її фармацевтично прийнятна сіль
CN104159589A (zh) * 2012-01-23 2014-11-19 坎-菲特生物药物有限公司 肝脏状况的治疗
PT2807178T (pt) 2012-01-26 2017-08-08 Inotek Pharmaceuticals Corp Polimorfos anidros de nitrato de (2r,3s,4r,5r)-5-(6-(ciclopentilamino)-9h-purin-9-il)-3,4-dihidroxitetrahidrofuran-2-il)}metilo e seus processos de preparação
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
US8822460B2 (en) 2012-04-06 2014-09-02 Janssen Pharmaceutica Nv Fused cyclopentyl antagonists of CCR2
AU2013290418B2 (en) 2012-07-19 2017-08-03 Chaozhong Cai Octahydro-cyclopentapyrrolyl antagonists of CCR2
JP6140825B2 (ja) 2012-08-09 2017-05-31 キャン−ファイト バイオファーマ リミテッドＣａｎ−Ｆｉｔｅ ＢｉｏＰｈａｒｍａ Ｌｔｄ． 性機能不全の治療に使用するためのａ３アデノシン受容体リガンド
NZ630759A (en) 2013-03-15 2017-07-28 Inotek Pharmaceuticals Corp Ophthalmic formulations comprising an a1 agonist
IL242723B (en) 2015-11-23 2019-12-31 Can Fite Biopharma Ltd A3 adenosine receptor ligand for the treatment of ectopic fat accumulation
KR102445887B1 (ko) 2016-04-21 2022-09-21 아스트로사이트 파마슈티컬스, 인코포레이티드 신경계 및 심혈관계 병태 치료를 위한 화합물 및 방법
IL254535A0 (en) * 2017-09-17 2017-11-30 Can Fite Biopharma Ltd Adenosine a3 receptor ligand for use in the management of cytokine release syndrome
IL276358B2 (en) 2018-02-09 2024-11-01 Astrocyte Pharmaceuticals Inc Compounds and methods for treating addiction and related disorders
EA202190576A1 (ru) 2018-09-26 2021-09-03 Астросайт Фармасьютикалс, Инк. Полиморфные соединения и их применение
IL264112A (en) 2019-01-06 2020-07-30 Fishman Pnina An a3 adenosine receptor ligand for use for reducing level of adipocytes
IT202300014340A1 (it) 2023-07-10 2025-01-10 Consiglio Nazionale Ricerche Trattamento di malattie associate alla disfunzione del gene ocrl.

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443836A (en) * 1993-03-15 1995-08-22 Gensia, Inc. Methods for protecting tissues and organs from ischemic damage
DE69428536T2 (de) 1993-07-13 2002-06-06 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A3 -adenosin -rezeptor agonisten
US5688774A (en) 1993-07-13 1997-11-18 The United States Of America As Represented By The Department Of Health And Human Services A3 adenosine receptor agonists
GB2289218A (en) * 1994-05-06 1995-11-15 Merck & Co Inc Inhibition of TNFalpha production with agonists of the A2b subtype of the adenosine receptor
RU2071770C1 (ru) 1994-12-14 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака шейки матки и яичников
RU2071771C1 (ru) 1995-01-11 1997-01-20 Владислав Алексеевич Шматко Способ лечения рака молочной железы
AU750322B2 (en) * 1997-05-09 2002-07-18 Trustees Of The University Of Pennsylvania, The Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
IL121272A (en) 1997-07-10 2000-06-01 Can Fite Technologies Ltd Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
US6048865A (en) * 1997-07-29 2000-04-11 Medco Research, Inc. N6 -substituted-adenosine-5'-uronamides as adenosine receptor modulator
AU8764398A (en) 1997-07-29 1999-02-22 Medco Research, Inc. N6-substituted-adenosine-5'-uronamides as adenosine receptor modulators
WO1999020284A1 (en) * 1997-10-23 1999-04-29 Trustees Of The University Of Pennsylvania Methods for reducing ischemic injury of the heart via the sequential administration of monophosphoryl lipid a and adenosine receptor agents
EP1011608A4 (en) 1998-06-08 2002-05-15 Epigenesis Pharmaceuticals Inc COMPOSITION AND METHOD FOR THE PREVENTION AND TREATMENT OF HEART AND NEUTRAL FAILURE OR DAMAGE RELATED TO ISCHEMIA, ENDOTOXIN RELEASE, ARDS OR CALLED BY THE ADDITION OF SPECIFIC MEDICINES
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
IL127947A0 (en) * 1999-01-07 1999-11-30 Can Fite Technologies Ltd Pharmaceutical use of adenosine agonists
CA2361614C (en) 1999-02-01 2008-08-26 University Of Virginia Patent Foundation Compositions for treating inflammatory response
IL131096A (en) 1999-07-26 2004-09-27 Can Fite Technologies Ltd Method for preparing a composition derived from muscle tissue

Also Published As

Publication number Publication date
CN100358512C (zh) 2008-01-02
US7064112B1 (en) 2006-06-20
ES2296637T3 (es) 2008-05-01
HU226913B1 (en) 2010-03-01
IL133680A0 (en) 2001-04-30
JP2003514771A (ja) 2003-04-22
BR0013905A (pt) 2003-07-15
HK1052653B (zh) 2008-08-01
JP2007204496A (ja) 2007-08-16
PL199852B1 (pl) 2008-11-28
PL356469A1 (en) 2004-06-28
AU782826B2 (en) 2005-09-01
CN1391468A (zh) 2003-01-15
KR100584797B1 (ko) 2006-06-02
RU2002109228A (ru) 2004-01-10
CA2384111C (en) 2008-05-27
DE60037277T2 (de) 2008-10-09
PT1261322E (pt) 2008-01-09
HUP0203870A3 (en) 2005-07-28
JP4980530B2 (ja) 2012-07-18
HK1052653A1 (zh) 2003-09-26
CA2384111A1 (en) 2001-03-22
EP1261322A2 (en) 2002-12-04
WO2001019360A3 (en) 2002-09-19
KR20020038749A (ko) 2002-05-23
AU6863400A (en) 2001-04-17
DE60037277D1 (de) 2008-01-10
RU2239455C2 (ru) 2004-11-10
DK1261322T3 (da) 2008-04-07
KR20060036490A (ko) 2006-04-28
WO2001019360A2 (en) 2001-03-22
KR100674529B1 (ko) 2007-01-30
HUP0203870A2 (hu) 2003-03-28
US20060084626A1 (en) 2006-04-20
EP1261322B1 (en) 2007-11-28

Similar Documents

Publication Publication Date Title
MXPA02002546A (es) Composiciones farmaceuticas que comprenden un receptor agonista o antagonista de la adenosina.
MXPA03005257A (es) Composiciones frarmaceuticas de un agonista del receptor de nmda.
HUP0401437A3 (en) Adenosine a3 receptor agonists
PT1192169E (pt) C-pirazoles agonistas do receptor a2a
HUP0203638A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them and their use
AU6497701A (en) Melanocortin receptor agonists
MXPA03001143A (es) Derivados de 4-fenil-piridina como antagonistas del receptor de neuroquinina-1.
HUP0201545A3 (en) Betha2-adrenergic receptor agonists and pharmaceutical compositions containing them
EG24194A (en) 5ht-a-partial agonist pharmaceutical compositions
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
IL160715A0 (en) Pharmaceutical compositions containing an a1 adenosine receptor antagonist
AU2371400A (en) Vitronectin receptor antagonist pharmaceuticals
AU2002351730A1 (en) Glucagon receptor antagonists/inverse agonists
AU2001286409A1 (en) N-methyl-d-aspartate receptor antagonists
HUP0201300A3 (en) Il-8 receptor antagonist imidazoidinylidene-2-imino derivatives and pharmaceutical compositions containing them
EG24025A (en) Vitronectin receptor antagonist
AU1100300A (en) Piperidyloxadiazoles as dopamine receptor antagonists
IL146471A0 (en) Orally active a1 adenosine receptor agonists
AU5861900A (en) Receptor agonists and antagonists
AU2001249573A1 (en) Chemokine receptor antagonists
ZA200201780B (en) Vitronectin receptor antagonists.
HUP0200057A3 (en) Dopamine d1 receptor agonist compounds, pharmaceutical compositions containing them and their use
AU2574801A (en) Selective iGLUR5 receptor antagonists
IL131864A0 (en) Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
IL160438A0 (en) Pharmaceutical compositions containing an angiotensin ii receptor antagonist

Legal Events

Date Code Title Description
FG Grant or registration